Botanix Pharmaceuticals Valuation

Q: What is the Fair Price of BOT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

BOT (A$0.32) is trading below our estimate of [[fair value]] (A$8.06)

Is BOT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BOT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BOT (A$0.32) is trading below our estimate of fair value (A$8.06)

Significantly Below Fair Value: BOT is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BOT?

Key metric: As BOT barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for BOT. This is calculated by dividing BOT's market cap by their current book value.
What is BOT's PB Ratio?
PB Ratio	5.3x
Book	AU$108.73m
Market Cap	AU$581.59m

BOT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	242.7x
Enterprise Value/EBITDA	-36.1x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does BOT's PB Ratio compare to its peers?

The above table shows the PB ratio for BOT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	6.4x
MYX Mayne Pharma Group	0.8x	110.0%	AU$363.5m
NUZ Neurizon Therapeutics	9x	n/a	AU$92.5m
SNT Syntara	13.5x	43.7%	AU$63.2m
VLS Vita Life Sciences	2.4x	n/a	AU$117.1m
BOT Botanix Pharmaceuticals	5.3x	99.4%	AU$581.6m

Price-To-Book vs Peers: BOT is good value based on its Price-To-Book Ratio (5.3x) compared to the peer average (6.4x).

Price to Book Ratio vs Industry

How does BOT's PB Ratio compare vs other companies in the AU Pharmaceuticals Industry?

3 Companies	Price / Book	Estimated Growth	Market Cap
LGP Little Green Pharma	0.5x	110.1%	US$25.51m
EOF Ecofibre	0.4x	n/a	US$9.97m
CGB Cann Global	0.5x	n/a	US$3.69m

No more companies available in this PB range

3 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: BOT is expensive based on its Price-To-Book Ratio (5.3x) compared to the Australian Pharmaceuticals industry average (4.4x).

Price to Book Ratio vs Fair Ratio

What is BOT's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BOT PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	5.3x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate BOT's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

AVITA Medical

US$337.6m

Operates as a regenerative medicine company in the United States and internationally.

AVH

US$3.93

2.3%

20.4%

Medical Developments International

AU$47.3m

Manufactures and distributes emergency medical solutions in Australia, Europe, the United States, and internationally.

MVP

AU$0.42

-5.6%

-46.8%

Little Green Pharma

AU$39.2m

Engages in the cultivation, production, and distribution of medicinal cannabis products in Australia and internationally.

LGP

AU$0.14

10.2%